David S Schoenhaut

6509015, Jan 21, 2003

Mar 31, 2000

09/540018

Jochen G. Salfeld - North Grafton MA
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westboro MA
Boris Labkovsky - Framingham MA
John A. Mankovich - Andover MA
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Shrewsbury MA
David Schoenhaut - Clifton NJ
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA
Alison J. Wilton - Cambridge, GB

BASF Aktiengesellschaft - Ludwigshafen

A61K 39395

4241421, 424 852, 4241451, 424800, 424810

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) are disclosed. These antibodies have high affinity for hTNF (e. g. , K =10 M or less), a slow off rate for hTNF dissociation (e. g. , K =10 sec or less) and neutralize hTNF activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF and for inhibiting hTNF activity, e. g. , in a human subject suffering from a disorder in which hTNF activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

7223394, May 29, 2007

Mar 7, 2001

09/801185

Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - Cambridge, GB
Hendricus R. J. M. Hoogenboom - Maastricht, BE
Zehra Kaymakcalan - Westboro MA, US
Boris Labkovsky - Framingham MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Comberton, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton MA, US
David Schoenhaut - Garfield NJ, US
Tristan J. Vaughan - Impington, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB

Abbott Biotechnology Ltd - Hamilton

A61K 39/395

4241421, 4241451, 4241581, 53038815, 53038823, 5303892

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

7541031, Jun 2, 2009

Apr 17, 2007

11/787901

Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton Highlands MA, US
Hendricus R. J. M. Hoogenboom - Hasselt, BE
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB

Abbott Biotechnology Ltd.

A61K 39/395
A61K 31/495

4241421, 4241451, 4241581, 424810, 514249

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

7588761, Sep 15, 2009

Sep 21, 2005

11/233252

Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton MA, US
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge MA, US

Abbott Biotechnology Ltd. - Hamilton

A61K 39/395
C07K 16/24

4241421, 4241451, 4241581, 424484, 424486, 424810, 53038815, 53038823, 530868

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

8197813, Jun 12, 2012

Mar 10, 2009

12/401469

Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westboro MA, US
Boris Labkovsky - Framingham MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Shrewsbury MA, US
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB

Abbott Biotechnology Ltd. - Hamilton

A61K 39/395
C07K 16/24

4241421, 4241451, 4241581, 53038815, 53038823

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

8372400, Feb 12, 2013

Oct 13, 2009

12/578487

Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton Highlands MA, US
Hendricus R. J. M. Hoogenboom - Hasselt, BE
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB

Abbott Biotechnology Ltd. - Hamilton

A61K 39/395

4241421, 4241451, 4241581, 424810, 530868

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

8372401, Feb 12, 2013

May 8, 2012

13/466892

Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton Highlands MA, US
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB

Abbott Biotechnology Ltd. - Hamilton

A61K 39/395
C07K 16/00

4241421, 4241451, 4241581, 53038815, 53038823

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

8414894, Apr 9, 2013

Dec 30, 2011

13/340805

Jochen G. Salfeld - North Grafton MA, US
John A. Mankovich - Andover MA, US
Deborah J. Allen - London, GB
Hendricus R.J.M. Hoogenboom - Hasselt, BE
Boris Labkovsky - Framingham MA, US
Brian T. McGuinness - Cambridge, GB
Paul Sakorafas - Newtown Highlands MA, US
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB
Zehra Kaymakcalan - Westboro MA, US
Andrew J. Roberts - Cambridge, GB
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB

Abbott Biotechnology Ltd. - Hamilton

A61K 39/395
C07K 16/00
G01N 33/53

4241421, 4241451, 4241581, 4241781, 435 71, 435 77, 435 79, 53038815, 53038823, 5303911

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.